Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma
The Oncologist · 08.05.2026 · 31 (6)
DOI: 10.1093/oncolo/oyag185 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 08.05.2026. Verfasst von Jianwei Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking …. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Pancreatic Neoplasms, Stomach Neoplasms, Intestinal Neoplasms. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Technologies Research and Development.
Abstract (Originalsprache)
Purpose
Despite emerging genomic discoveries, few have been translated into practical management strategies for people with gastroenteropancreatic neuroendocrine carcinoma (GEPNEC). This study aims to identify key genes and their potential clinical relevance to improve care for this patient group.
Methods
In the analytical cohort, we reported high-frequency alteration genes, significantly mutated genes, and driver genes and defined their overlap as key genes. Genotypes were identified as Type I/II/III. For further validation, we prospectively recruited eligible patients to build a main cohort, through which we performed univariate/multivariate Cox regression analysis and sketched Kaplan–Meier survival plot. Targetable genes were defined by the OncoKB database.
Results
The analytical cohort consisted of 124 patients. The genes most frequently altered were TP53 (78%), RB1 (35%), APC (27%), and KRAS (17%). Key genes were identified as TP53, RB1, APC, and KRAS. The main cohort included 171 patients. We defined the genotype “Type I” (defined as TP53/RB1 co-alterations) as a reference. In midgut/hindgut NEC, we identified a “Type II” subtype characterized by mutations in either APC or KRAS alterations without TP53/RB1 co-alterations. Type II of midgut/hindgut NEC patients had elevated carcinoembryonic antigen (CEA) levels and longer median overall survival (mOS) than others (not reached vs 11.4 months, HR = 0.19[0.08, 0.44], P = .0028). In foregut NEC, we identified “Type III” (either APC/KRAS alterations or TP53/RB1 co-alterations). Type III of foregut NEC patients showed shorter mOS than others (11.6 vs 19.0 months, HR = 1.93[1.13, 3.25], P = .01). Type II patients who received non-platinum/etoposide (EP) chemotherapy had longer first-line progression-free survival (PFS) compared to EP regimen. They also benefited from second-line immunotherapy. Targeted therapy as second-line was also suitable for targetable patients (longer PFS than others: 12.5 vs 3.0 months, HR = 0.40[0.21-0.75], P = .0017).
Conclusions
Our study identified key gene-based genotypes (Type II/III) of distinct GEPNEC patients and yielded their prognosis and therapeutic utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute, Beijing 100143, China.
- Department of Radiation Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 51…
- Medical Department, Nanjing Geneseeq Technology Inc., Nanjing 210032, China.
- Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100143, China.
ORCID-Profile: Jianwei Zhang, Lin Shen
Förderung
- Key Technologies Research and Development
Zitieren
APA
Zhang, J., Zhang, P., Zhang, Y., Hu, Q., Li, J., Zhang, X., Li, J., Wang, X., Zhou, J., Lu, Z., Peng, Z., Sun, Y., Wang, S., Lu, M., & Shen, L. (2026). Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag185
Vancouver
Zhang J, Zhang P, Zhang Y, Hu Q, Li J, Zhang X, et al. Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag185
BibTeX
@article{Zhang2026,
author = {Zhang, Jianwei and Zhang, Panpan and Zhang, Yanyan and Hu, Qiaomian and Li, Jie and Zhang, Xiaotian and Li, Jian and Wang, Xicheng and Zhou, Jun and Lu, Zhihao and Peng, Zhi and Sun, Yu and Wang, Sha and Lu, Ming and Shen, Lin},
title = {Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {6},
doi = {10.1093/oncolo/oyag185}
}
EUVIMED